Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Protalix BioTherapeutics's operating income for the twelve months ending Jun 30, 2026 was $23.29M, up 183.1% year over year. For fiscal 2025 it was -$5.50M, down 240.4% from the year before. The highest annual figure on record is $10.46M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.50M | -240.4% |
| FY2024 | Dec 31, 2024 | $3.92M | -62.6% |
| FY2023 | Dec 31, 2023 | $10.46M | – |
| FY2022 | Dec 31, 2022 | -$13.01M | – |
| FY2021 | Dec 31, 2021 | -$20.46M | -855.1% |
| FY2020 | Dec 31, 2020 | $2.71M | – |
| FY2019 | Dec 31, 2019 | -$10.72M | – |
| FY2018 | Dec 31, 2018 | -$19.31M | – |
| FY2017 | Dec 31, 2017 | -$34.52M | – |
| FY2016 | Dec 31, 2016 | -$33.16M | – |
| FY2015 | Dec 31, 2015 | -$23.67M | – |
| FY2014 | Dec 31, 2014 | -$28.56M | – |
| FY2013 | Dec 31, 2013 | -$34.06M | – |
| FY2012 | Dec 31, 2012 | -$12.17M | – |
| FY2011 | Dec 31, 2011 | -$36.53M | – |
| FY2010 | Dec 31, 2010 | -$29.97M | – |
| FY2009 | Dec 31, 2009 | -$31.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.67M | +298.6% |
| Q1 FY2026 | Mar 31, 2026 | $21.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.66M | -164.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.13M | -46.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.15M | – |
| Q4 FY2024 | Dec 31, 2024 | $7.21M | – |
| Q3 FY2024 | Sep 30, 2024 | $3.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.43M | -111.9% |
| Q1 FY2024 | Mar 31, 2024 | -$4.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.89M | – |
| Q2 FY2023 | Jun 30, 2023 | $20.42M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.71M | -301.0% |
| Q3 FY2021 | Sep 30, 2021 | -$1.89M | -140.2% |
| Q2 FY2021 | Jun 30, 2021 | -$9.17M | -516.6% |
| Q1 FY2021 | Mar 31, 2021 | -$3.71M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.84M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.69M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.53M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.67M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.74M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.15M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.58M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.77M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.81M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.72M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.65M | – |
| Q2 FY2016 | Jun 30, 2016 | -$9.93M | – |
See a number that looks wrong?